Precision Dosing of Alemtuzumab

Completed · Not applicable

Conditions studied: Allogeneic Hematopoietic Cell Transplantation

In brief

The purpose of this study is to conduct a pilot trial of a Precision Dosing approach to alemtuzumab dosing for allogeneic hematopoietic cell transplantation of patients with non-malignant diseases. The investigators will measure the ability to use a population PK model of alemtuzumab to target patient Day 0 alemtuzumab levels to 0.15-0.6ug/mL in a pilot study of 20 patients.

Key facts

Study ID
NCT03302754
Run by
Children's Hospital Medical Center, Cincinnati
People needed
12
Starts
2017-10-05
Expected to finish
2019-03-10
Last updated by the study team
2019-10-04

Who can join

Age: 0 and older, up to 30. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.